Passage Bio, Inc., a biotechnology firm specializing in biological products, has transferred its stock listing from The Nasdaq Global Select Market to The Nasdaq Capital Market. The transition, ...

Outlines Strategic Priorities Passage Bio Inc (NASDAQ: PASG) announced initial safety and biomarker data from three Cohort 1 patients in the ongoing global Phase 1/2 upliFT-D clinical trial ...

PHILADELPHIA, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative ...

The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics ...

Given this risk, we thought we'd take a look at whether Passage Bio (NASDAQ:PASG) shareholders should be worried about its cash burn. In this article, we define cash burn as its annual (negative) free ...

PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) has shared updated findings from its ongoing Phase 1/2 upliFT-D clinical trial, which evaluates PBFT02 as a potential treatment for ...

Beta Bionics has set the terms for its plan to go public, with a goal of raising at least $114 million to support its ...

Nasdaq (Nasdaq: NDAQ) announced today that in 2024, it welcomed 171 initial public offerings (IPOs), raising a total of $22.7 billion. A total of 123 operating companies and 48 SPACs listed on ...

Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and ...